Part II · Mechanism
Ghrelin, the hunger hormone
Ghrelin is the body's main hunger signal, produced mostly in the stomach. It rises before meals and falls after eating, and after weight loss it runs higher than before, pushing you to eat more.
The short answer
Ghrelin is the body's main hunger signal. It is made mostly in the stomach, and it runs higher after weight loss. That elevation is measurable and persists for at least a year. Contrary to a common assumption, ESG has not been shown to lower it.
Hunger after weight loss is partly hormonal and predictable. Importantly, it is not a failure of discipline.
The "time to eat" signal
Ghrelin is produced mostly in the stomach. It rises before meals (the building sense that it is time to eat is largely ghrelin at work) and falls once you have eaten.C-II-03
Ghrelin does not act alone; it is paired against leptin, the signal that reports how much energy is stored. In rough terms, ghrelin says eat and leptin says enough. Weight loss tips both signals the wrong way at once.C-II-01
What weight loss does to it
After weight loss, ghrelin tends to run higher than it did before, and the elevation has been measured over time. Twelve months out, ghrelin was still running high, leptin was around 35% below baseline, and hunger was measurably greater than before the diet started.C-II-04
This is one of the concrete ways the body defends the weight range it has been holding: it uses hunger.
What stomach procedures do to it
Because so much ghrelin is made in the stomach, it seems reasonable to assume that a procedure that reduces the stomach's capacity would also turn the hunger signal down. The measurements do not support that assumption.
Higher
Fasting ghrelin, GLP-1 and PYY, 18 months after ESG in a randomized trial, rather than lower C-IV-05
152 vs 89 min
Time for the stomach to half-empty after the procedure, versus controls: the mechanism at work
A separate study found no change in fasting ghrelin at all. What the randomized trial did find was delayed emptying (the stomach empties considerably more slowly, and that delay persisted at twelve months), alongside rises in fasting ghrelin, GLP-1 and PYY at 18 months. In practical terms, the procedure works through capacity and timing, which is also how the FDA's own classification describes it. It is not a ghrelin-lowering operation.
There is an endoscopic therapy aimed directly at ghrelin, and it is a different procedure. Gastric mucosal ablation selectively devitalizes the ghrelin-producing lining of the stomach. It is investigational (an international expert consensus uses that exact word), and the first-in-human trial performed it as a separate step before a gastroplasty, which is itself a sign that the two are doing different jobs.C-IV-06
Everself does not offer it. Ghrelin can be targeted directly, in principle, but with a different procedure from the one most people assume.
References
- Vargas EJ, et al. Effect of endoscopic sleeve gastroplasty on gastric emptying, motility and hormones. Gut. 2023. PMID 36241388
- Lopez-Nava G, et al. Gut hormone changes after endoscopic sleeve gastroplasty. Obes Surg. 2020. PMID 32193741
- Gadi SRV, et al. Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty: a first-in-human trial. Endoscopy. 2026. PMID 41760139
- Kumbhari V, et al. Safety Framework for Gastric Mucosal Ablation: International Expert Consensus. Obes Surg. 2026. PMID 42142234
- Sumithran P, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. NEJM. 2011.